M2e-immobilized gold nanoparticles as influenza A vaccine: Role of soluble M2e and longevity of protection

Vaccine

Volumn 33, Issue 20, 2015, Pages 2307-2315

  Tao, Wenqian ^a   Gill, Harvinder S ^a  

^a Texas Tech University   (United States)

Author keywords

Influenza; Long term protection; Nanoparticle conjugated M2e; Soluble M2e; Universal vaccine

Indexed keywords

GOLD NANOPARTICLE; INFLUENZA VACCINE; M2 MEMBRANE PROTEIN; MEMBRANE PROTEIN; UNCLASSIFIED DRUG; CPG-OLIGONUCLEOTIDE; GOLD; IMMOBILIZED PROTEIN; IMMUNOLOGICAL ADJUVANT; M2 PROTEIN, INFLUENZA A VIRUS; MATRIX PROTEIN; METAL NANOPARTICLE; OLIGODEOXYRIBONUCLEOTIDE; VACCINE; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CPG ISLAND; DRUG EFFICACY; DRUG FORMULATION; FEMALE; IMMUNE RESPONSE; IN VITRO STUDY; INFLUENZA A; INFLUENZA VIRUS A; LONGEVITY; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; DISEASE MODEL; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); ORTHOMYXOVIRIDAE INFECTIONS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; FEMALE; GOLD; IMMOBILIZED PROTEINS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; METAL NANOPARTICLES; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; ORTHOMYXOVIRIDAE INFECTIONS; VACCINE POTENCY; VIRAL MATRIX PROTEINS;

EID: 84928591245     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.03.063     Document Type: Article

References (44)

1. WHO Influenza (seasonal) 2014, http://wwwwhoint/mediacentre/factsheets/fs211/en/.
2. Neumann G., Kawaoka Y. The first influenza pandemic of the new millennium. Influenza Other Respir Viruses 2011, 5:157-166.
3. Kilbourne E.D. Influenza pandemics of the 20th century. Emerg Infect Dis 2006, 12:9.
4. Beigel J., Farrar J., Han A., Hayden F., Hyer R., De Jong M. Avian influenza A (H5N1) infection in humans. N Engl J Med 2005, 353.
5. Gerdil C. The annual production cycle for influenza vaccine. Vaccine 2003, 21:1776-1779.
6. Cox R., Brokstad K., Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 2004, 59:1-15.
7. Subbarao K., Murphy B.R., Fauci A.S. Development of effective vaccines against pandemic influenza. Immunity 2006, 24:5-9.
8. Allen P.J. Avian influenza pandemic: not if, but when. Pediatr Nurs 2005, 32:76-81.
9. Reid A.H., Fanning T.G., Janczewski T.A., McCall S., Taubenberger J.K. Characterization of the 1918 Spanish influenza virus matrix gene segment. J Virol 2002, 76:10717-10723.
10. 2 protein is an integral membrane protein expressed on the infected-cell surface. Cell 1985, 40:627-633.
11. Holsinger L.J., Alams R. Influenza virus M2 integral membrane protein is a homotetramer stabilized by formation of disulfide bonds. Virology 1991, 183:32-43.
12. De Filette M., Fiers W., Martens W., Birkett A., Ramne A., Löwenadler B., et al. Improved design and intranasal delivery of an M2e-based human influenza A vaccine. Vaccine 2006, 24:6597-6601.
13. Huleatt J.W., Nakaar V., Desai P., Huang Y., Hewitt D., Jacobs A., et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 2008, 26:201-214.
14. Tompkins S.M., Zhao Z.-S., Lo C.-Y., Misplon J.A., Liu T., Ye Z., et al. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 2007, 13.
15. Ingrole R.S., Tao W., Tripathy J.N., Gill H.S. Synthesis and immunogenicity assessment of elastin-like polypeptide-M2e construct as an influenza antigen. Nano LIFE 2014, 4.
16. Ibañez L.I., Roose K., De Filette M., Schotsaert M., De Sloovere J., Roels S., et al. M2e-displaying virus-like particles with associated RNA promote T helper 1 type adaptive immunity against influenza A. PLOS ONE 2013, 8:e59081.
17. Neirynck S., Deroo T., Saelens X., Vanlandschoot P., Jou W.M., Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999, 5:1157-1163.
18. Fan J., Liang X., Horton M.S., Perry H.C., Citron M.P., Heidecker G.J., et al. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 2004, 22:2993-3003.
19. Fu T-M., Grimm K.M., Citron M.P., Freed D.C., Fan J., Keller P.M., et al. Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys. Vaccine 2009, 27:1440-1447.
20. Wibowo N., Chuan Y.P., Lua L.H., Middelberg A.P. Modular engineering of a microbially-produced viral capsomere vaccine for influenza. Chem Eng Sci 2013, 103:12-20.
21. Seth A., Ritchie F.K., Wibowo N., Lua L.H., Middelberg A.P. Non-carrier nanoparticles adjuvant modular protein vaccine in a particle-dependent manner. PLOS ONE 2014, 10:e0117203.
22. Chowdhury M.Y., Li R., Kim J-H., Park M.-E., Kim T.-H., Pathinayake P., et al. Mucosal vaccination with recombinant lactobacillus casei-displayed cta1-conjugated consensus matrix protein-2 (sM2) induces broad protection against divergent influenza subtypes in BALB/c mice. PLOS ONE 2014, 9:e94051.
23. Kimling J., Maier M., Okenve B., Kotaidis V., Ballot H., Plech A. Turkevich method for gold nanoparticle synthesis revisited. J Phys Chem B 2006, 110:15700-15707.
24. Tkachenko A., Xie H., Franzen S., Feldheim D.L. Assembly and characterization of biomolecule-gold nanoparticle conjugates and their use in intracellular imaging nanobiotechnology protocols 2005, 85-99. Humana Press. S.J. Rosenthal, D.W. Wright (Eds.).
25. Lévy R., Thanh N.T., Doty R.C., Hussain I., Nichols R.J., Schiffrin D.J., et al. Rational and combinatorial design of peptide capping ligands for gold nanoparticles. J Am Chem Soc 2004, 126:10076-10084.
26. Li Z., Jin R., Mirkin C.A., Letsinger R.L. Multiple thiol-anchor capped DNA-gold nanoparticle conjugates. Nucleic Acids Res 2002, 30:1558-1562.
27. MacDairmid A., Gallagher M., Banks J. Structure of dithiothreitol monolayers on Au (111). J Phys Chem B 2003, 107:9789-9792.
28. Zhang F., Skoda M.W., Jacobs R.M., Zorn S., Martin R.A., Martin C.M., et al. Gold nanoparticles decorated with oligo (ethylene glycol) thiols: protein resistance and colloidal stability. J Phys Chem A 2007, 111:12229-12237.
29. Schollbach M., Zhang F., Roosen-Runge F., Skoda M.W., Jacobs R.M., Schreiber F. Gold nanoparticles decorated with oligo (ethylene glycol) thiols: surface charges and interactions with proteins in solution. J Colloid Interface Sci 2014, 426:31-38.
30. Wibowo N., Chuan Y.P., Seth A., Cordoba Y., Lua L.H., Middelberg A.P. Co-administration of non-carrier nanoparticles boosts antigen immune response without requiring protein conjugation. Vaccine 2014, 32:3664-3669.
31. Ulery B.D., Kumar D., Ramer-Tait A.E., Metzger D.W., Wannemuehler M.J., Narasimhan B. Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases. PLoS ONE 2011, 6:e17642.
32. Phanse Y., Carrillo-Conde B.R., Ramer-Tait A.E., Broderick S., Kong C.S., Rajan K., et al. A systems approach to designing next generation vaccines: combining α-galactose modified antigens with nanoparticle platforms. Sci Rep 2014, 4.
33. Zhao L., Seth A., Wibowo N., Zhao C.-X., Mitter N., Yu C., et al. Nanoparticle vaccines. Vaccine 2014, 32:327-337.
34. Kim M.-C., Song J.-M., Eunju O., Kwon Y.-M., Lee Y.-J., Compans R.W., et al. Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Mol Ther 2012, 21:485-492.
35. Poeck H., Wagner M., Battiany J., Rothenfusser S., Wellisch D., Hornung V., et al. Plasmacytoid dendritic cells, antigen, and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T-cell help. Blood 2004, 103:3058-3064.
36. Zabel F., Kündig T.M., Bachmann M.F. Virus-induced humoral immunity: on how B cell responses are initiated. Curr Opin Virol 2013, 3:357-362.
37. Abraham E., Peter B., Himmel G. Management of rheumatoid arthritis: rationale for the use of colloidal metallic gold. J Nutr Environ Med 1997, 7:295-305.
38. Chen Y.-S., Hung Y.-C., Liau I., Huang G.S. Assessment of the in vivo toxicity of gold nanoparticles. Nanoscale Res Lett 2009, 4:858-864.
39. Cho W.-S., Cho M., Jeong J., Choi M., Cho H.-Y., Han B.S., et al. Acute toxicity and pharmacokinetics of 13 nm-sized PEG-coated gold nanoparticles. Toxicol Appl Pharmacol 2009, 236:16-24.
40. Khlebtsov N., Dykman L. Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies. Chem Soc Rev 2011, 40:1647-1671.
41. Lasagna-Reeves C., Gonzalez-Romero D., Barria M., Olmedo I., Clos A., Ramanujam V.S., et al. Bioaccumulation and toxicity of gold nanoparticles after repeated administration in mice. Biochem Biophys Res Commun 2010, 393:649-655.
42. Murphy C.J., Gole A.M., Stone J.W., Sisco P.N., Alkilany A.M., Goldsmith E.C., et al. Gold nanoparticles in biology: beyond toxicity to cellular imaging. Acc Chem Res 2008, 41:1721-1730.
43. Sonavane G., Tomoda K., Makino K. Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size. Colloids Surf B: Biointerfaces 2008, 66:274-280.
44. Allabashi R., Stach W., de la Escosura-Muñiz A., Liste-Calleja L., Merkoçi A. ICP-MS: a powerful technique for quantitative determination of gold nanoparticles without previous dissolving. J Nanopart Res 2009, 11:2003-2011.